Ray Dalio's TGTX Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 342,149 shares of TG Therapeutics, Inc. (TGTX) worth $12.36 M, representing 0.05% of the portfolio. First purchased in 2025-Q3, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Ray Dalio has initiated a new position in TGTX, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's TG Therapeutics (TGTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly TG Therapeutics (TGTX) Trades by Ray Dalio
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2025 | +342,149 | New Buy | 342,149 | $36.13 |
Ray Dalio's TG Therapeutics Investment FAQs
Ray Dalio first purchased TG Therapeutics, Inc. (TGTX) in Q3 2025, acquiring 342,149 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held TG Therapeutics, Inc. (TGTX) for 1 quarters since Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's largest addition to TG Therapeutics, Inc. (TGTX) was in Q3 2025, adding 342,149 shares worth $12.36 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 342,149 shares of TG Therapeutics, Inc. (TGTX), valued at approximately $12.36 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, TG Therapeutics, Inc. (TGTX) represents approximately 0.05% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's peak holding in TG Therapeutics, Inc. (TGTX) was 342,149 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.